OnKure Therapeutics, Inc. financial data

Symbol
OKUR on Nasdaq
Location
6707 Winchester Circle, Suite 400, Boulder, CO
State of incorporation
DE
Fiscal year end
December 31
Former names
Reneo Pharmaceuticals, Inc. (to 10/2/2024)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.35K % +26.7%
Debt-to-equity 8.64 % -26.4%
Return On Equity -51.2 % +17.6%
Return On Assets -47.1 % +15.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.4M shares -1.1%
Common Stock, Shares, Outstanding 3.34M shares -90.1%
Entity Public Float 151M USD +291%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 3.34M shares -1.12%
Weighted Average Number of Shares Outstanding, Diluted 3.34M shares -1.12%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24M USD -51.3%
General and Administrative Expense 21.6M USD -7.24%
Operating Income (Loss) -45.6M USD +37.2%
Net Income (Loss) Attributable to Parent -41M USD +39.2%
Earnings Per Share, Basic 2.9 USD/shares +80.6%
Earnings Per Share, Diluted 2.9 USD/shares +80.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.7M USD +417%
Cash, Cash Equivalents, and Short-term Investments 76.7M USD
Assets, Current 77M USD -40.2%
Property, Plant and Equipment, Net 59K USD -88.8%
Operating Lease, Right-of-Use Asset 440K USD -56.3%
Other Assets, Noncurrent 147K USD +81.5%
Assets 77.6M USD -40.5%
Accounts Payable, Current 237K USD -90.4%
Accrued Liabilities, Current 725K USD -93.3%
Liabilities, Current 3.25M USD -76.1%
Operating Lease, Liability, Noncurrent 379K USD -53.3%
Liabilities 3.63M USD -76.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD
Retained Earnings (Accumulated Deficit) -236M USD -23.8%
Stockholders' Equity Attributable to Parent 74M USD -35.6%
Liabilities and Equity 77.6M USD -40.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21M USD -132%
Net Cash Provided by (Used in) Financing Activities 1.01M USD
Net Cash Provided by (Used in) Investing Activities 13.8M USD -25.7%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 3.34M shares -90.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.26M USD -169%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.7M USD +417%
Deferred Tax Assets, Valuation Allowance 49.9M USD +54.8%
Deferred Tax Assets, Gross 50M USD +53.9%
Operating Lease, Liability 665K USD -41.5%
Payments to Acquire Property, Plant, and Equipment 172K USD +291%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41M USD +39.2%
Lessee, Operating Lease, Liability, to be Paid 754K USD -38.8%
Property, Plant and Equipment, Gross 254K USD -54.2%
Operating Lease, Liability, Current 286K USD -12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 285K USD -25.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 371K USD -2.63%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 89K USD -7.29%
Lessee, Operating Lease, Liability, to be Paid, Year Three 285K USD -25.2%
Deferred Tax Assets, Operating Loss Carryforwards 23.5M USD +43.4%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 11.4M USD +61.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 34K USD -88.1%
Operating Lease, Payments 96K USD -32.4%
Additional Paid in Capital 310M USD +1.47%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 16K USD -61%
Deferred Tax Assets, Net of Valuation Allowance 126K USD -55%
Share-based Payment Arrangement, Expense 4.21M USD -15.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%